But he added that the company didn't have the resources to quickly increase production.
"Yes, we need more funding to take the drug materials that we have currently to convert that into upwards 100 more courses of therapy, or more," Garabedian said. "To be able to ramp up to the thousands of doses would require a larger investment and more time that could take upwards of a year or more to be able to generate enough courses to treat thousands of patients."
Garabedian said that the company has been in contact with health-care agencies.
"We have been communicating to all of the government agencies, the World Health Organization," he said. "We've had people at the table at every substantive discussion around how to manage this Ebola outbreak and have educated everybody who's interested in learning about our technology and the drug we have available.
Read MoreEbola: A closer look at this 'frightening disease'
"Everybody knows we're here. They know the drug we have, and we're waiting for that call."
Garabedian said that the company has yet to examine its expected costs.
"Obviously, at this point we've not discussed or negotiated any costs or transfer or procurement, so if we got a request to really prepare and ramp up larger volumes of drugs, we would need to determine those costs and what kind of revenues would need to come into the company for us to be able to do that," he said.